Novo Nordisk began construction of a new $2 billion production facility in Clayton, NC that will produce active pharmaceutical ingredients (API) for a range of the company’s current and future GLP-1 and insulin products. When fully operational in 2020, the site will take on production capacity for diabetes care products in the U.S.
 
The new site is adjacent to Novo Nordisk’s existing 42,000 m² facility, which assembles and packages FlexPen and FlexTouch prefilled insulin devices for the U.S. market. The expansion is expected to create as many as 700 new jobs.  
 
“As the prevalence of diabetes has grown in the U.S., so too has the demand for effective treatments,” said Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk. “It gives me great pride to break ground on our new facility site in Clayton where we have an existing, strong organisation. This site will play a vital role in enabling us to meet the needs of people living with diabetes in the U.S. for years to come.”